Please provide your email address to receive an email when new articles are posted on . Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with ...

Please provide your email address to receive an email when new articles are posted on . Patients assigned liso-cel achieved longer median PFS and OS compared with standard of care. ORR was ...

Please provide your email address to receive an email when new articles are posted on . The agent induced a 97% ORR among patients with relapsed or refractory follicular lymphoma. Researchers observed ...

Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments. The TRANSCEND CLL 004 trial showed a 52.5% ...

Please provide your email address to receive an email when new articles are posted on . Liso-cel induced an 18% complete response/CRi rate among adults with relapsed or refractory CLL or SLL. Median ...

Mantle cell lymphoma is the fourth subtype of non-Hodgkin lymphoma that can be treated with this CAR T-cell therapy. Bristol Myers Squibb today announced 1 that FDA has approved lisocabtagene ...

Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma. The green light comes ...

Facing a diagnosis of large B-cell lymphoma that has relapsed or hasn’t responded to initial treatments can feel overwhelming. However, recent advancements in treatments — such as an approach known as ...

Please provide your email address to receive an email when new articles are posted on . Liso-cel’s price increased by more than $35,000 dollars between 2022 and 2023. The CAR T-cell therapy’s ICER ...

Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

A CAR T-cell therapy that promises fewer side effects, and possibly lower hospital costs, wins approval after lengthy delays. After delays that proved costly to investors, FDA today approved ...